This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Topiramate (TPM) is effective as mono- and adjunctive treatment for epilepsy and migraine in adults and children.1 Side effects may include headache, dizziness, drowsiness, gastrointestinal, and cognitive problems. Weight loss occur in 6 to 15% of the patients depending on dose in a dose-comparison trial of TPM as monotherapy in recently diagnosed partial epilepsy.2 With use of this side effect, TPM was found to be effective as treatment for adults with binge-eating disorder3 and for obesity in children with Prader–Willi syndrome.4 We systematically assessed the effect of TPM on cognition in obese children, who were included in an open label study on the effect of TPM on body mass index.
Methods.
We prospectively recruited 14 Dutch children from the outpatient clinics of pediatrics and pediatric neurology of our university hospital. Inclusion criteria were body mass index exceeding +2.3 SD corrected for gender and age, age 4 to 18 years, informed consent of parents and children older than 12 years, and failure of dietary measures or controlled exercises to reduce weight. Exclusion criteria were liver or kidney failure, untreated hypopituitary …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy
Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate
A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy
Obesity and overweight as CAE comorbidities and differential drug response modifiers